Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.

Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, Christensen MB, Vilsbøll T, Holst JJ, Rosenkilde MM, Knop FK.

Diabetes. 2019 May;68(5):906-917. doi: 10.2337/db18-1123. Epub 2019 Jan 9.

PMID:
30626611
2.

Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors.

Gabe MBN, Sparre-Ulrich AH, Pedersen MF, Gasbjerg LS, Inoue A, Bräuner-Osborne H, Hartmann B, Rosenkilde MM.

Biochem Pharmacol. 2018 Apr;150:97-107. doi: 10.1016/j.bcp.2018.01.040. Epub 2018 Feb 3.

PMID:
29378179
3.

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.

Gasbjerg LS, Christensen MB, Hartmann B, Lanng AR, Sparre-Ulrich AH, Gabe MBN, Dela F, Vilsbøll T, Holst JJ, Rosenkilde MM, Knop FK.

Diabetologia. 2018 Feb;61(2):413-423. doi: 10.1007/s00125-017-4447-4. Epub 2017 Sep 25.

PMID:
28948296
4.

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor.

Asmar M, Asmar A, Simonsen L, Gasbjerg LS, Sparre-Ulrich AH, Rosenkilde MM, Hartmann B, Dela F, Holst JJ, Bülow J.

Diabetes. 2017 Sep;66(9):2363-2371. doi: 10.2337/db17-0480. Epub 2017 Jun 30.

5.

GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release.

Sparre-Ulrich AH, Gabe MN, Gasbjerg LS, Christiansen CB, Svendsen B, Hartmann B, Holst JJ, Rosenkilde MM.

Biochem Pharmacol. 2017 May 1;131:78-88. doi: 10.1016/j.bcp.2017.02.012. Epub 2017 Feb 22.

6.

Signaling via G proteins mediates tumorigenic effects of GPR87.

Niss Arfelt K, Fares S, Sparre-Ulrich AH, Hjortø GM, Gasbjerg LS, Mølleskov-Jensen AS, Benned-Jensen T, Rosenkilde MM.

Cell Signal. 2017 Jan;30:9-18. doi: 10.1016/j.cellsig.2016.11.009. Epub 2016 Nov 16.

PMID:
27865873
7.

N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.

Hansen LS, Sparre-Ulrich AH, Christensen M, Knop FK, Hartmann B, Holst JJ, Rosenkilde MM.

Br J Pharmacol. 2016 Mar;173(5):826-38. doi: 10.1111/bph.13384. Epub 2016 Jan 30.

8.

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.

Sparre-Ulrich AH, Hansen LS, Svendsen B, Christensen M, Knop FK, Hartmann B, Holst JJ, Rosenkilde MM.

Br J Pharmacol. 2016 Jan;173(1):27-38. doi: 10.1111/bph.13323. Epub 2015 Nov 20.

9.

Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes.

Christensen M, Sparre-Ulrich AH, Hartmann B, Grevstad U, Rosenkilde MM, Holst JJ, Vilsbøll T, Knop FK.

Int J Obes (Lond). 2015 Nov;39(11):1651-4. doi: 10.1038/ijo.2015.136. Epub 2015 Jul 31.

PMID:
26228460
10.

Identification and functional comparison of seven-transmembrane G-protein-coupled BILF1 receptors in recently discovered nonhuman primate lymphocryptoviruses.

Spiess K, Fares S, Sparre-Ulrich AH, Hilgenberg E, Jarvis MA, Ehlers B, Rosenkilde MM.

J Virol. 2015 Feb;89(4):2253-67. doi: 10.1128/JVI.02716-14. Epub 2014 Dec 10.

11.

Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.

Christensen M, Calanna S, Sparre-Ulrich AH, Kristensen PL, Rosenkilde MM, Faber J, Purrello F, van Hall G, Holst JJ, Vilsbøll T, Knop FK.

Diabetes. 2015 Jan;64(1):72-8. doi: 10.2337/db14-0440. Epub 2014 Jul 22.

12.

Gating function of isoleucine-116 in TM-3 (position III:16/3.40) for the activity state of the CC-chemokine receptor 5 (CCR5).

Steen A, Sparre-Ulrich AH, Thiele S, Guo D, Frimurer TM, Rosenkilde MM.

Br J Pharmacol. 2014 Mar;171(6):1566-79. doi: 10.1111/bph.12553.

13.

International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A.

Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467.

14.

Extracellular disulfide bridges serve different purposes in two homologous chemokine receptors, CCR1 and CCR5.

Rummel PC, Thiele S, Hansen LS, Petersen TP, Sparre-Ulrich AH, Ulven T, Rosenkilde MM.

Mol Pharmacol. 2013 Sep;84(3):335-45. doi: 10.1124/mol.113.086702. Epub 2013 Jun 13.

PMID:
23765404
15.

Structural Diversity in Conserved Regions Like the DRY-Motif among Viral 7TM Receptors-A Consequence of Evolutionary Pressure?

Jensen AS, Sparre-Ulrich AH, Davis-Poynter N, Rosenkilde MM.

Adv Virol. 2012;2012:231813. doi: 10.1155/2012/231813. Epub 2012 Jul 30.

16.

Partial functional complementation between human and mouse cytomegalovirus chemokine receptor homologues.

Farrell HE, Abraham AM, Cardin RD, Sparre-Ulrich AH, Rosenkilde MM, Spiess K, Jensen TH, Kledal TN, Davis-Poynter N.

J Virol. 2011 Jun;85(12):6091-5. doi: 10.1128/JVI.02113-10. Epub 2011 Apr 13.

Supplemental Content

Loading ...
Support Center